ArticleFrontiers in reproductive health2026
TP53 codon 47 and 72 polymorphisms show no association with HPV in Zimbabwean women living with HIV and histologically confirmed cervical and vulvar disease.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Interaction between HIV and human papillomavirus (HPV) increases the risk of HPV persistence. However, a few studies have explored the interplay between host genetic factors and HPV in women living with HIV (WLWH). We report on a study investigating the role of TP53 mutations among HPV DNA-positive cervical and vulvar tissue from Zimbabwean WLWH. Methods: This cross-sectional study recruited 102 WLWH aged over 18 years, with histologically confirmed vulvar ( Results: The histological classifications had the following proportions: cervical intraepithelial neoplasia (CIN)1: 10%, CIN2: 4.5%, CIN3: 82%, and cervical cancer: 3.4%. Vulvar disease was classified as: vulvar intraepithelial neoplasia (VIN)3: 84.6%, and vulvar cancer (15.4%). HPV16 prevalence was 40% and 64% in vulvar tissue. Codon 72G and codon 47 T alleles had frequencies of 34.1% and 2.9% in cervical tissue, and 29.2% and 4.2% in vulvar tissue, respectively. There was no significant association between TP53 codon 72 and 47 mutations, and HPV genotypes ( Discussion and Conclusion: These findings underscore the need to conduct further research to identify other genetic variants within the TP53 gene that may contribute to the role of TP53 in HPV susceptibility that has been previously reported in other studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.